CPCCOEt
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (-)-ethyl (7E)-7-hydroxyimino-1,7a-dihydrocyclopropa[b]chromene-1a-carboxylate | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 179067-99-3  |
| ATC code | ? |
| PubChem | CID 6278000 |
| IUPHAR ligand | 1382 |
| ChEMBL | CHEMBL337583  |
| Chemical data | |
| Formula | C13H13NO4 |
| Mol. mass | 247.246 g/mol |
| SMILES | eMolecules & PubChem |
 (what is this?) (verify) |
CPCCOEt is a drug used in scientific research, which acts as a non-competitive antagonist at the metabotropic glutamate receptor subtype mGluR1, with high selectivity although only moderate binding affinity.[1][2] It is used mainly in basic research into the function of the mGluR1 receptor,[3][4] including the study of behavioural effects in animals including effects on memory and addiction.[5][6]
[edit] See also
[edit] References
- ^ Litschig S, Gasparini F, Rueegg D, Stoehr N, Flor PJ, Vranesic I, Prézeau L, Pin JP, Thomsen C, Kuhn R (March 1999). "CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding". Molecular Pharmacology 55 (3): 453–61. PMID 10051528.
- ^ Ott D, Floersheim P, Inderbitzin W, Stoehr N, Francotte E, Lecis G, Richert P, Rihs G, Flor PJ, Kuhn R, Gasparini F (November 2000). "Chiral resolution, pharmacological characterization, and receptor docking of the noncompetitive mGlu1 receptor antagonist (+/-)-2-hydroxyimino- 1a, 2-dihydro-1H-7-oxacyclopropa[b]naphthalene-7a-carboxylic acid ethyl ester". Journal of Medicinal Chemistry 43 (23): 4428–36. doi:10.1021/jm0009944. PMID 11087567.
- ^ Fukunaga I, Yeo CH, Batchelor AM (February 2007). "The mGlu1 antagonist CPCCOEt enhances the climbing fibre response in Purkinje neurones independently of glutamate receptors". Neuropharmacology 52 (2): 450–8. doi:10.1016/j.neuropharm.2006.08.014. PMID 17045308.
- ^ Sugiyama Y, Kawaguchi SY, Hirano T (February 2008). "mGluR1-mediated facilitation of long-term potentiation at inhibitory synapses on a cerebellar Purkinje neuron". The European Journal of Neuroscience 27 (4): 884–96. doi:10.1111/j.1460-9568.2008.06063.x. PMID 18279362.
- ^ Lominac KD, Kapasova Z, Hannun RA, Patterson C, Middaugh LD, Szumlinski KK (November 2006). "Behavioral and neurochemical interactions between Group 1 mGluR antagonists and ethanol: potential insight into their anti-addictive properties". Drug and Alcohol Dependence 85 (2): 142–56. doi:10.1016/j.drugalcdep.2006.04.003. PMID 16697125.
- ^ Kim J, Lee S, Park H, Song B, Hong I, Geum D, Shin K, Choi S (March 2007). "Blockade of amygdala metabotropic glutamate receptor subtype 1 impairs fear extinction". Biochemical and Biophysical Research Communications 355 (1): 188–93. doi:10.1016/j.bbrc.2007.01.125. PMID 17292864.
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
